Rising Prevalence and Technological Advancements Drive the Lymphedema Treatment Market

The “Global Lymphedema Treatment Market Size, Share, Growth Analysis, By End-User, By Product, By Condition Type, By Treatment Type – Industry Forecast 2023-2030” report has been added to ResearchAndMarkets.com’s offering.

The global lymphedema treatment market, valued at $786.53 million in 2021, is projected to grow significantly, reaching $1.74 billion by 2030. This robust growth is expected to occur at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period of 2023-2030.

Lymphedema: A Growing Health Concern

Lymphedema, characterized by abnormal swelling due to a malfunctioning lymphatic system, primarily affects the lower extremities but can also impact the upper extremities and genitalia. It can result from various factors, including infections like filariasis and as a side effect of breast cancer treatment. Notably, lymphedema is estimated to affect 40% of breast cancer patients.

Market Drivers

Several factors are contributing to the growth of the lymphedema treatment market:

  1. Increasing Prevalence: The rising prevalence of lymphedema and breast cancer cases is a significant driver for the market. The condition can occur at any stage of cancer or following treatment, even years later.
  2. Product Innovation: Major industry players are introducing new products, driving demand for high-quality treatment options, and leveraging technological advancements to develop innovative solutions.
  3. Technological Advancements: Technological developments in lymphedema treatment methods are expected to accelerate market growth. These innovations are improving the effectiveness of treatment and enhancing patient outcomes.
  4. Government Initiatives: Supportive government programs and reimbursement policies are facilitating market growth by reducing the financial burden on patients and healthcare providers.


Despite advancements, there is currently no permanent cure for lymphedema, posing a challenge to market growth. Additionally, the rising costs associated with procedures and treatments may limit market expansion.

Market Trends

Key trends driving market growth include the development of innovative and cutting-edge treatments to lower the risks associated with lymphedema. The expansion of the healthcare industry and increased healthcare innovation are also expected to fuel growth.

Segments Covered

The global lymphedema treatment market is segmented based on various factors, including end-user (hospitals, ambulatory surgical centers, specialty clinics, others), product (compression bandages, compression stockings, pneumatic compression devices, others), affected area (genital, lower extremity, upper extremity, others), age group (adult, geriatric), route of administration (oral, injectable, others), type (primary, secondary lymphedema), condition type (cancer, cardiovascular diseases, inflammatory diseases, others), treatment type (compression therapy, surgery, drug therapy, laser therapy, others), and region (North America, Europe, Asia-Pacific, South America, MEA).

Key Players

Leading companies in the global lymphedema treatment market include Bio Compression Systems, Tactile Medical, Medi, Lympha Press, Sigvaris, BSN Medical, L&R USA Inc., Devon Medical Products, 3M Health Care, JOBST USA, Thuasne, Wright Therapy Products, BioHorizons IPH, Inc., Haddenham Healthcare, ArjoHuntleigh, Paul Hartmann, Bioventus, Baxter International Inc., CircAid Medical Products, Inc., Essity Aktiebolag, and others.

For more information about this report visit https://www.researchandmarkets.com/r/wp2yyd

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy